Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference
Kinnate Biopharma Inc. (Nasdaq: KNTE) announced that its CEO, Nima Farzan, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 1:40 p.m. ET. In addition, the Kinnate management team will hold investor meetings during the conference. Interested parties can access a live webcast of the session on the Kinnate website, with a replay available for 90 days post-event. Kinnate is dedicated to developing targeted therapies for cancer, focusing on oncogenic drivers that lack effective treatments. The company is advancing its clinical programs for solid tumors and aims to provide new, effective cancer therapies.
- None.
- None.
SAN FRANCISCO and SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 1:40 p.m. ET / 10:40 a.m. PT.
Members of the Kinnate management team will also host investor meetings during the conference.
Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Kinnate.com. A webcast replay will be made available following the event for 90 days.
About Kinnate Biopharma Inc.
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such as non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine. The company is driven by the urgency and knowledge that patients are waiting for new, effective cancer medicines. For more information, visit Kinnate.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are also intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends. Such expectations and projections may never materialize or may prove to be incorrect. These forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors as described under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 that we have filed with the Securities and Exchange Commission (the “SEC”), as well as in our subsequent filings we make with the SEC. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. Investors should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Our forward-looking statements speak only as of the date of this release, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason in the future.
Investor & Media Contact:
Priyanka Shah | Priyanka.Shah@kinnate.com | +1-908-447-6134
FAQ
When is Kinnate Biopharma's CEO participating in a fireside chat?
What conference is Kinnate Biopharma attending in February 2023?
How can investors access the Kinnate Biopharma conference webcast?
What is Kinnate Biopharma's focus in cancer therapy?
How long will the Kinnate Biopharma conference webcast be available for replay?
